GB-5001
Phase 1Once-monthly donepezil injection for dementia; in the Phase 1 multiple-dose study, 140 mg every four weeks reached steady state within three to four doses.
FROM PUBLIC EVENTS · 2026-11-18
Early clinical · first deals Has Phase 1 results for its dementia injection and keeps signing platform co-development and evaluation deals with drugmakers in Korea and abroad.
Roles often seen at this stageResearch & development · Clinical & PV · Manufacturing & MSAT
An Osong-based company developing improved drugs with InnoLAMP, its platform for long-acting injectables whose effect lasts long after a single shot.
Once-monthly donepezil injection for dementia; in the Phase 1 multiple-dose study, 140 mg every four weeks reached steady state within three to four doses.
Long-acting injectable platform; under an evaluation contract it is being applied to candidates provided by China's UBT.
Signed a long-acting injectable platform evaluation contract with China's UBT.
Announced safety and tolerability results from the GB-5001 Phase 1 multiple-dose study.
Signed a three-way agreement with Samsung Bioepis and Epis NexLab to develop a long-acting obesity treatment.
Official role guide
Observed 2026-11-18
Information from a role guide does not establish a current vacancy.
A brief based on selected official material, not an exhaustive product or vacancy list.